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Design of triphasic poly(lactic-co-glycolic acid)
nanoparticles containing a perﬂuorocarbon phase
for biomedical applications†
Edyta Swider, a Alexander H. J. Staal,a N. Koen van Riessen,a Linsey Jacobs,a
Paul B. White,b Remco Fokkink,c Geert-Jan Janssen,e Eric van Dinther,a
Carl G. Figdor, a I. Jolanda M. de Vries, ad Olga Koshkina ‡*a
and Mangala Srinivas ‡*a
Poly(lactic-co-glycolic acid) (PLGA) particles are very widely used, particularly for drug delivery, including
commercial clinical formulations. Adding perﬂuorocarbon (PFC) enables in vivo imaging and
quantiﬁcation of the PLGA particles through 19F NMR, MRS or MRI. PFCs are both hydrophobic and
lipophobic at the same time. This property makes their encapsulation in particles challenging, as it
requires the addition of a third immiscible phase during the emulsiﬁcation process. Here we explore how
diﬀerent parameters aﬀect the miniemulsion formation of particles loaded with perﬂuoro-15-crown-5-
ether (PFCE). By changing the concentration of surfactant and type of solvent, we were able to control
the radius of synthesized particles, between 85–200 nm. We assessed stability and release from the
particles at diﬀerent pH values, showing that hydrophobic agents are released from the particles by
diﬀusion rather than degradation. With cell experiments, we show that primary human dendritic cells
take up the particles without any apparent eﬀect, including on cell migration. In summary, the control of
synthesis conditions leads to particles with suﬃcient PFCE encapsulation, which are suitable for drug
loading and cell labeling, and do not aﬀect cell viability or functionality. Finally, these nanoparticles can
be produced at GMP-grade for clinical use.
Introduction
Recent developments in the eld on nanomedicine have
focused on multifunctional theranostic devices. Such thera-
nostic devices, encapsulating both a contrast agent for imaging,
e.g. magnetic resonance imaging (MRI), and a drug for therapy,
allow not only for the delivery of a therapeutic compound to the
site of interest, but also give the ability to visualize and monitor
therapy and progression of the disease.1 For these purposes, the
use of biodegradable polymeric particles is of great interest due
to their ease of processing, biological stability, low toxicity, and
eﬀectiveness as delivery agents.2 Poly(lactic-co-glycolic acid)
(PLGA) is particularly attractive for the synthesis of nano-
particles, as PLGA is biocompatible, biodegradable, and shows
long-term storage stability.3 PLGA nanoparticles can be modi-
ed, for example with contrast agents and drugs, by either
covalent coupling or non-covalent loading using the hydro-
phobic eﬀect.4–6 PLGA protects the drug from fast degradation
and the release time of the encapsulated cargo from the parti-
cles can be modulated by altering the synthesis parameters and
polymer composition.7
Loading the particles with liquid peruorocarbons (PFCs) for
uorine (19F) MRI is advantageous for biomedical use, as it can
be used for in vivo non-invasive imaging. Fluorine is essentially
absent from biological tissues, therefore, 19F MRI results in
high specicity of images and moreover, enables the quanti-
cation of the signal, including determination of 19F content and
particularly quantication of 19F-labeled cells directly from
image data.8,9 PFCs are simultaneously hydrophobic and
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lipophobic synthetic organic compounds with a high payload of
uorine atoms,10 with a long history of clinical application,
initially as blood substitutes and more recently for imaging
applications.11,12 To overcome the immiscibility of PFCs, liquid
PFCs are usually delivered as surfactant-stabilized PFC emul-
sions for 19F MRI. However, the colloidal stability of PFC
emulsions is relatively low, especially at high concentrations
required for cells loading, which further may lead to accumu-
lation in organs and poor biodistribution.9,13–16 The stability can
be improved with the use of phospholipids or poloxamers,
however both types of surfactants exhibit some disadvantages,
e.g. they are prone to hydrolysis and oxidation (phospholipids)
or they tend to form highly viscous dispersions (poloxamers).17
Encapsulation of PFCs into polymeric nanoparticles is rela-
tively new to the eld and has some specic advantages,
particularly for cell loading and imaging. Here, perluoro-15-
crown-5-ether (PFCE) is of special interest, as it is chemically
and biologically inert and consists of 20 chemically equivalent
19F nuclei, leading to a singlet in NMR spectra, which is an
important factor for quantication and MR imaging.18,19 PFCE-
loaded PLGA particles can be synthesized using a miniemulsion
formulation technique (Fig. 1).3 It has been previously shown
that parameters such as type of solvent and surfactant, and
concentration of surfactant and polymer can inuence the
characteristics of PLGA nanoparticles prepared by the solvent
evaporation method.20
Aiming at diﬀerent applications, such as cell tracking and
imaging of drug delivery, it is important to control the properties
of PLGA–PFC particles, including diameter, diameter distribu-
tion, uorine content, and encapsulation eﬃciency of hydro-
phobic drug or other agents. Particle size and size distribution
inuence the in vivo distribution, cell uptake, biological fate,
toxicity and the targeting ability. For example, Waiczies et al.
reported on uorine-rich emulsion particles, where larger parti-
cles (280 nm in radius) were more readily taken up by dendritic
cells (DCs) and promoted the DCs maturation process.21 These
particle characteristics can also aﬀect drug loading, drug release,
and stability of particles.22 However, systematic study of
peruorocarbon-loaded PLGA nanoparticles have not been re-
ported thus far. Hence, there is little prior work describing
a systematic study of triphasic PLGA–PFC systems, although
these have been shown to have a very high loading and excellent
stability.3,23 In this work, we explore the inuence of diﬀerent
synthesis parameters on the radius, homogeneity, stability and
encapsulation eﬃciency of PLGA–PFCE nanoparticles and the
inuence of the PFC phase on particle characteristics. We focus
only on PLGA–PFCE nanoparticles, which are very diﬀerent from
PLGA particles that are extensively described in the literature. We
also investigate the impact of PFC-encapsulation on the release
characteristics of PLGA particles. For this, we introduce nile blue
dye into the nanoparticles, as a model hydrophobic drug. Finally,
we compare the cellular uptake of diﬀerent particles in primary
human monocyte-derived dendritic cells (moDCs), and the
eﬀects of uptake on cell viability and functionality. Overall, the
objective of the present study is to show how diﬀerent synthesis
parameters inuence the synthesis of PLGA particles with a third
PFC phase, with a view to biomedical applications.
Results and discussion
Change in surfactant concentration and type of solvent
inuences the nal properties of particles
The main parameters, which aﬀect the synthesis of PLGA
particles are type and concentration of surfactant, concentra-
tion of polymer, and type of solvent for the organic phase
(Scheme 1).3,21,24–26
Loading the particles with PFC alters the properties of min-
iemulsions, as PFCs form their own phase in solutions. Among
diﬀerent surfactants, polyvinyl alcohol (PVA) with low molec-
ular weight (10 kDa) resulted in nanoparticles with a small
hydrodynamic radius (Rh), and high PFCE loading. Thus, by
reducing the concentration of surfactant, in this case PVA,
which is perhaps the most oen used surfactant for synthesis of
PLGA particles, we could obtain particles with a larger size. This
result is similar to PLGA particles without PFC (Fig. 2).20,26,27
However, the polydispersity of particles also increased, while
the encapsulation yield of PFCE dropped, perhaps because at
lower concentrations of surfactant, stabilization of the PFCE-
droplets was not achieved. In a miniemulsion, diameter and
diameter distribution of droplets directly depend on the
Fig. 1 Schematic representation of miniemulsion formulation method. PLGA and PFCE are added to surfactant solution under sonication,
followed by solvent evaporation. Next, particles are washed, freeze-dried, and collected as a dry powder.
This journal is © The Royal Society of Chemistry 2018 RSC Adv., 2018, 8, 6460–6470 | 6461
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concentration of surfactant. A higher concentration of surfac-
tant in the aqueous phase (in this case 2.0 wt%) leads to
a suﬃcient coverage of the interface between droplet and
aqueous phase by surfactant, which stabilizes the emulsion
droplets and prevents the coalescence. Hence, a higher
concentration of surfactant results in more homogenous
particles with a narrower size distribution. This eﬀect is re-
ected in lower PDI values (Fig. S1†), as well as in lower stan-
dard deviation between measurements. Thus, particles
prepared with 2 wt% of surfactant have lower PDI values and the
diameter measurements also display better reproducibility than
at lower concentration of surfactant. Interestingly, several other
surfactants that are commonly used in synthesis of PLGA
particles without PFC,27,28 were not able to stabilize particles
when the PFCE phase was added (Table S1†).
Furthermore, increasing concentration of polymer, while
keeping the volume of organic phase and other parameters
constant, resulted in larger particles with lower PFCE loading
(Fig. 2B). Typically, increasing concentration of polymer leads to
the formation of bigger droplets due to increased viscosity of
the organic phase.20,29,30 The total amount of obtained nano-
particle yield was slightly higher when we increased the
concentration of PLGA, while the overall amount of PFCE in the
whole batch was at around 20 mg for all three concentrations of
polymer (Table 1). Finally, the type of solvent used for mini-
emulsion process did not aﬀect the properties of the nal
particles. Thus, using chloroform or ethyl acetate, which are
both higher polarity solvents resulted in similar particles as
with dichloromethane (DCM) (Table S2†).
Along with the miniemulsion technique, nanoprecipitation
is another common technique for the synthesis of PLGA nano-
particles. We investigated nanoprecipitation to better under-
stand the formation of nanoparticles. As nanoprecipitation
does not involve the use of shear forces; it is not suitable for the
encapsulation of PFCE. However, we modied a typical nano-
precipitation procedure by applying sonication during the
addition of the organic to aqueous phase; this resulted in
increased size and polydispersity of nanoparticles, and low
PFCE encapsulation (Table S2†).
Combination of DCM with other solvents with diﬀerent
polarities inuences the size of particles
Interestingly, in contrast to replacing DCM with another water
immiscible solvent (Table S2†), mixing DCM with solvents of
Scheme 1 Schematic representation of parameters, which aﬀect properties of nanoparticles, tested in this study, including factors that resulted
in nanoparticles with low PDI, narrow size distribution and high PFCE content.
Fig. 2 Results of DLS (black) and NMR (blue) measurements of nanoparticles prepared with diﬀerent concentration of surfactant (A) or PLGA (B).
(A) Inﬂuence of PVA concentration on particle radius and PFCE encapsulation. Particles were prepared using following concentrations of
surfactant: 0.4 wt%, 1.2 wt% and 2 wt%. Here, the concentration of polymer in organic phase was the same for all samples, 1.75 wt%. Better
reproducibility of particle radius was achieved with higher concentration of surfactant. Furthermore, higher concentration of PVA resulted in
nanoparticles with higher encapsulation eﬃciency of PFCE. Error bars represent the standard deviation (n ¼ 3) (B) inﬂuence of concentration of
PLGA on particle radius and PFCE encapsulation. Higher concentration of polymer resulted in slightly larger particles, but lower encapsulation
eﬃciency. For all samples concentration of surfactant at 2 wt% was used. DLS results are presented in black and NMR results in blue. DLS: c(NP)¼
0.1 mg ml1, NMR with TFA as internal reference.
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higher or lower polarity, while keeping the concentration of
surfactant and polymer constant (2 and 1.75 wt% respectively),
resulted in altered size of particles, with eﬃcient encapsulation
of PFCE (Table S3†). Thus, the combination of DCM with the
higher polarity solvent acetonitrile (MeCN, relative polarity
0.460) or lower relative polarity solvent toluene (relative polarity
0.099) resulted in smaller or bigger size respectively, according
to Transmission Electron Microscopy (TEM) (Fig. 3B and C).
The diﬀerences between solvents result from the interfacial
tension between aqueous and organic phase. The interfacial
tension between aqueous and organic phase is higher for
solvents with lower polarity, such as DCM + toluene mixture.31
Bigger droplets have lower surface-to-volume ratio. Therefore,
for oil-in-water miniemulsion the formation of bigger droplets
is facilitated, when solvents with lower polarity are used for
dispersed phase, compared to solvents with higher polarity.31
An additional reason for the smaller size of particles prepared
with DCM + MeCN mixture could be a diﬀusion of water
miscible MeCN into aqueous phase directly aer the formation
of the droplets. This diﬀusion results in faster shrinking of the
droplets and thus in smaller size of the nal particles. However,
further experiments are necessary to conrm this mechanism.
TEM data analysis of these nanoparticles diﬀered from the
results of Dynamic Light Scattering (DLS) (Table S3†). TEM
results showed a bimodal size distribution (151 nm and 85 nm
fractions) of nanoparticles prepared with DCM + toluene as
solvent (Fig. 3C), while DLS measurements of these particles
showed a radius of 195 nm. These DLS measurements were
Table 1 Characterization of nanoparticles prepared with combination of diﬀerent solvents
Nanoparticle
(solvent type)
R (nm)  SD
(cryoSEM)
Rh  SD
(DLS at 173)
PFCE encapsulation
(wt%)
Dye concentration
mg ml1
DCM 120  20 93  5 22 8
DCM + MeCN 90  20 85  2 19 6
DCM + toluene 253  62, 110  25 117  32 19 12
Fig. 3 (A–C) Nanoparticle size distribution based on TEM images. Bimodal size distribution can be observed for particles made with the
combination of DCM with toluene solvent (3C). (D–F) Multi-angle LS results, where extrapolation q/ 0 results in inverse z-average radii <Rh>1/z
of 182, 163 and 308 nm for DCM, DCM + MeCN and DCM + toluene nanoparticles respectively. (G–I) CryoSEM images, here both fractions of
particles are visible for particles made with DCM + toluene (cNP ¼ 10 mg ml1). Also, some larger particles could be found with samples made
either with DCM only or with DCM + MeCN solvents.
This journal is © The Royal Society of Chemistry 2018 RSC Adv., 2018, 8, 6460–6470 | 6463
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done with backscatter detection at 173, which is less sensitive
to the presence of larger particles, as larger particles primarily
scatter light at forward angles. For particles larger than l/20 (l is
wavelength of the laser) the normalized single particle scat-
tering intensity the particle form factor P(q) becomes dependent
on scattering angle, represented by the scattering vector q.
Thus, the values of the diﬀusion coeﬃcient at single measure-
ment angles are apparent values. Therefore, to obtain the
absolute z-average of the diﬀusion coeﬃcient for calculation of
absolute hydrodynamic radius, the apparent values of the
diﬀusion coeﬃcient need to be extrapolated q / 0, which
corresponds to P(q) ¼ 1.32–34 To investigate this discrepancy
between TEM and single-angle DLS, we characterized the
particles with multi-angle DLS.
Fig. 3D–F shows the angular dependency of the inverse
hydrodynamic radius 1/Rh, which was obtained from apparent
diﬀusion coeﬃcients with the Stokes–Einstein equation.
Extrapolation q/ 0 results in inverse z-average of radii <Rh>1/z
of 182, 163 and 308 nm for DCM, DCM + MeCN and DCM +
toluene nanoparticles respectively, with the m2 values of second
cumulant from cumulant analysis of autocorrelation function at
q ¼ 90of 0.13, 0.08 and 0.27 (Fig. 3D–F).32 Typically, particles
with m2 values smaller than 0.05 are considered as mono-
disperse, while values higher than 0.2 are described as poly-
disperse.32 As the size distribution of particle seems to be non-
Gaussian according to TEM, especially for toluene particles, we
did not recalculate m2 values into PDI value. Further analysis of
angular dependency of DCM + toluene particles indicates the
presence of two size fractions, which were also visualized by
TEM. Thus, when only apparent values from q ¼ 30–70 are
used, the resulting <Rh>1/z ¼ 510 nm, while extrapolation of
bigger angles results in <Rh>1/z ¼ 182 nm. Generally, the
hydrodynamic radii obtained from DLS are bigger than the radii
from TEM, indicating that particles shrink when dried for TEM.
Especially, in the case of DCM + MeCN particles this eﬀect
seems to be quite pronounced, as the hydrodynamic radius is
three times higher than the TEM-determined radius. To study
this behaviour further we measured cryogenic Scanning Elec-
tron Microscopy (cryoSEM), which enables imaging of particles
in a solution-like state. CryoSEM demonstrates that themajority
of DCM + MeCN particles have an approximate radius around
65–90 nm, however, some particles have a radius around 125–
175 nm. With LS, only this fraction of bigger particles could be
detected. The results from cryoSEM on DCM + toluene particles
conrm the presence of both sizes 90–130 nm and 180–230 nm.
We also observed two fractions of particles in multi-angle LS as
presented in Fig. 3C. Thus, cryoSEM conrms the results, which
were obtained with LS.
The size of particles aﬀects the release rate of hydrophobic
agent
The release rate is a very important parameter when developing
systems suitable for diﬀerent biomedical applications, as it
determines whether the nanoparticles will be able to reach the
site of interest, before signicant degradation and loss of active
component has occurred. Factors inuencing the release rate
include e.g. particle radius and pH of the environment. The pH
of themedium has a signicant inuence on PLGA degradation,
as a lower pH increases the degradation rate of polymer
chains.35
To study the eﬀect of size and PFCE-loading on release, we
synthesized particles with the addition of uorescent dye, nile
blue, as a model compound for hydrophobic drugs, such as
paclitaxel, which have previously been encapsulated in PLGA
nanoparticles.36 Concentration of dye varied between diﬀerent
nanoparticles and increased with an increase in nanoparticle
radius (Table 1), as determined by ultraviolet/visible (UV/vis)
spectroscopy. The particles were incubated at 37 C in solu-
tions with pH values of 4.0, 5.5 and 8.5 to compare the release in
acidic and alkaline conditions. These pH values were chosen
based on the pH of diﬀerent subcellular compartments, namely
lysosomes, endosomes and mitochondria respectively. A study
by Panyam et al. showed that PLGA nanoparticles of approxi-
mate mean radius of 0.05 mm, incubated at 37 C in pH 7.4
maintained their structural integrity for up to 20–30 days, fol-
lowed by the formation of pores, deformation and fusion of
particles.37 Thus, we expect PLGA–PFCE particles to remain
stable aer in vivo injection, until they are taken up the immune
cells and reach the targeted site.
The percentage of released dye was calculated based on the
UV/vis results (Fig. 4A–C). Mid-size and bigger particles, which
were synthesized with DCM (Fig. 4A) and DCM + toluene
(Fig. 4C), showed higher burst release of encapsulated dye at pH
4 aer 6 hours. Even at later time points the release remained
higher than at higher pH. In case of DCM particles, the release
at pH 8.5 seems gradual, while at pH 5.5 faster release was
observed within rst two days and saturated aerwards. Larger
particles display faster release within rst two days, followed by
saturation of both release curves. The release of dye from
smaller particles was generally higher compared to both other
samples. This trend can be explained by the fact that smaller
particles have a larger surface area to volume ratio. With a larger
surface area, water has better accessibility to enter the particles,
resulting in an increase of degradation and release of the
encapsulated compound. In the case of smaller particles, the
release at pH 4 was also faster than at higher pH, although the
diﬀerence was less pronounced than with larger particles.
It has been previously demonstrated that smaller nano-
particles display higher polymer degradation and release rates
during the initial phase compared to larger particles.38 In our
experiment, we also observed faster release of dye from DCM +
MeCN particles (Fig. 4B) during the rst 4 days of incubation
when compared to DCM + toluene particles with larger radius
(Fig. 4C). This trend can be explained by the fact that smaller
particles have a larger surface area to volume ratio; with a larger
surface area, water has better accessibility can more readily
enter the particle, which further results in increased release of
the encapsulated compound. While replicating the pH of
various cell compartments, our model/assay lacks the presence
of various enzymes that can inuence the release.
To detect any changes in the average radius of nanoparticles
and PDI upon incubation, we measured samples at various time
points using DLS. The results are presented in Fig. 4D–F, and
6464 | RSC Adv., 2018, 8, 6460–6470 This journal is © The Royal Society of Chemistry 2018
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Fig. S3† (PDI). We observed a slow gradual decrease in particle
radius (Fig. 4D–E) with an average reduction of about 10 nm
within 24 days, for particles prepared with DCM and DCM +
MeCN solvents (93 to 80 nm and 85 to 75 nm respectively). No
signicant changes in the radius of particles formulated with
DCM + toluene mixture were detected (Fig. 4F).
In general, the size of particles decreased only slightly during
the whole period, indicating that diﬀusion of the dye rather
than particle degradation caused release. Note, however, that
the dye itself has an adsorption peak close to the wavelength of
the laser and could aﬀect size determination. The increase in
radius of DCM-toluene particles at 0 h time point could be due
to agglomeration of the sample. However, the backscattering set
up, which we used for size control during the release experi-
ment, was not able to detect the fraction of bigger size fraction,
which we detected with TEM and with multi-angle DLS. With
smaller particles, a low fraction of larger particles aﬀected
determination of size, as shown in the previous section.
Therefore, the limitations of a backscattering set up should be
taken into account when looking at the results of these size
measurements.
Overall, we found that PFCE-loaded particles show similar
trends in release as PLGA nanoparticles without PFCE. In
literature, PLGA particles do not show signicant changes in
size until up to 14 days of incubation in ref. 7, 37 and 39. For
MRI applications, PFCs are usually used as an emulsion, which
are stabilized by surfactants. The colloidal stability of these
emulsions is usually low, in a range of hours to days especially
at higher concentrations, as the stabilization of the PFC phase is
a challenge due to solubility properties of PFCs. By encapsula-
tion of this third PFC phase in the PLGA matrix, we obtained
particles that were stable for at least 21 days at 37 C, which is
a signicant improvement over many formulations of PFC
emulsions. Furthermore, the stability of the particles, which
were lyophilized and stored in a freezer, is at least 6 months.
To assess the inuence of the third phase on the encapsu-
lation of the hydrophobic agent, we synthesized particles
encapsulating nile blue, and with or without the addition of
PFCE. The highest encapsulation of nile blue was achieved with
nanoparticles prepared with the use of DCM as solvent, both
with and without the addition of PFCE, as presented in the
Fig. S4.† Furthermore, the diﬀerence in nile blue encapsulation
between these particles was minimal. Thus, we conclude that
the incorporation of even relatively large amounts of PFC does
not signicantly aﬀect the encapsulation and release of hydro-
phobic agents from the PLGA particles.
Nanoparticles are suitable for the loading of cells
To study the uptake of PFCE–PLGA nanoparticles, we loaded
human moDCs, as used in clinical trials,40 with the same
particles that were used for the dye release experiment, followed
by either 1 or 24 hours of incubation at 37 C, depending on the
assay. We chose DCs as a model for a therapeutic cell type, due
to their use in cancer immunotherapy a fast-growing eld. We
have previously shown that nanoparticle-loaded DCs can be
imaged in vivo, using 19F MRI.3,41 However, here we focused on
the chemical optimization of the particles and ensuring that
they are located intracellularly.
We used confocal microscopy to determine the intracellular
presence of PFCE–PLGA particles in moDCs. Aer incubation
with particles for 24 hours, cells were stained for the early
Fig. 4 Cumulative dye release and changes in particle diameter after incubation at diﬀerent pH. Faster dye release was observed for smallest
particles (B), when compared to particles emulsiﬁed with DCM solvent (A), while larger particles resulted in slower release (C). DLS analysis of
incubated samples, showed a slow gradual decrease in particles radius (D–F). Lines indicate trend of the data. NPs ¼ nanoparticles.
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endosomal marker EEA1 and the late endosomal/lysosomal
marker LAMP1 to study the potential intracellular localization
of nanoparticles. As presented in Fig. 5A and S3A and B†,
uorescent signal from the particles (arrows) partially overlaps
with the EEA1 signal. More co-localization of nanoparticles was
observed with the LAMP1 uorescent signal. Part of the uo-
rescent signal coming from the nanoparticles did not localize
with neither EEA1 nor LAMP1 signal. As explained in a previous
study,42 lack of co-localization could mean that some nano-
particles escape from the endosomal pathway. Another expla-
nation could be that nile blue leaked out of the particles
resulting in the signal detection outside of the endosomes or
lysosomes.
Size of particles is an important factor in biodistribution,
and in obtaining therapeutic eﬀectiveness. For example, PLGA
nanoparticles smaller than 50 nm in radius have lower plasma
protein adsorption on their surface and lower hepatic ltra-
tion.43 It has been shown that larger particles can be taken up
more eﬃciently by phagocytic cells than particles of smaller
radius.44 Particles larger than 250 nm in radius are typically
taken up via phagocytosis, while the uptake of smaller
nanoparticles occurs via endocytosis. Other particle character-
istics which can aﬀect the cellular uptake include charge, shape
and surface topology.21 Here, we show that all three sizes of
particle were readily taken up by the cells. However, uptake may
diﬀer with cell type, including other DC subsets, macrophages
or non-phagocytic cells. Thus, synthesizing particles of diﬀerent
sizes is crucial, as it gives the ability to target diﬀerent types of
cells.
One of the applications of PFCE–PLGA nanoparticles is their
use as cell tracking agents for 19F MRI. To investigate whether
nanoparticle-loaded cells can be detected with 19F MRI, we rst
incubated moDCs in the presence of DCM, DCM + MeCN or
DCM + toluene particles and then imaged them aer 3 days of
incubation. As shown is Fig. 5B, we were able to detect the
uorine signal from all three samples, using a biocompatible
imaging sequence and within a reasonable imaging time (15
minutes). The diﬀerences in the signal intensity are due to
diﬀerent encapsulation of PFCE among the nanoparticles used
for this assay. To investigate whether uptake aﬀects cell func-
tionality, we studied cell migration; both the velocity and the
distance covered by the labelled cells. The results of the
Fig. 5 Eﬀect of nanoparticles on monocyte-derived DCs. (A) Confocal microscope images of nanoparticle uptake by DCs. Fluorescent signal
coming from the nanoparticles partially overlaps with the signal of the early endosomal marker EEA1. Higher colocalization of nanoparticles was
observed with the signal of late endosomal/lysosomal marker LAMP1. (B) 1H/19F MRI image showing the signal of 5  106 cells loaded with
diﬀerent nanoparticles. Here, PFCE–PLGA particles, at 10 mg ml1 concentration, were used as a reference. (C) Nanoparticles do not aﬀect the
migration of dendritic cells. The graph represents average velocity of unloaded cells and cells loaded with nanoparticles. (D) The graph shows the
viability of cells after incubation with various nanoparticles for 72 hours. No signiﬁcant inﬂuence on cell viability was observed. Error bars
represent the standard deviation (n ¼ 3).
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measurements of average cell velocity are presented in Fig. 5C.
We observed an increase in velocity of cells incubated with
particles when compared to control cells (in red), which corre-
sponds to the fact that nanoparticle uptake can induce the
migration of DCs.45 The mean velocity was 0.56  0.22, 0.79 
0.34, 1.19  0.53 and 1.11  0.41 mm min1 for unloaded
controls, DCM nanoparticle, DCM + MeCN nanoparticle or
DCM + toluene nanoparticle-loaded cells respectively. The
trajectory of migrating cells for all four conditions is presented
in Fig. S5.† We further conrmed the cell viability using stan-
dard viability assay (Fig. 5D). Our results, show that the particles
are suitable for cell labelling and imaging with 19F MRI, and
have no signicant eﬀect on viability or functionality.
Conclusions
The size of particles, size distribution and degradation are
important factors for various biomedical applications,
including controlled delivery of drugs, drug release and cell
uptake. Control of these properties of nanoparticles is crucial
for optimal particle performance. In this study, we have shown
that a narrow size distribution and high 19F loading in PFCE–
PLGA nanoparticles can be achieved by using an optimal
concentration of surfactant and the right solvent. We also
showed that nanoparticle size has a strong inuence on the
encapsulation and release of the encapsulated cargo. Here, we
used nile blue as a model for a hydrophobic agent, such as
paclitaxel. PFCE–PLGA nanoparticles can be further adapted for
targeting by the addition of targeting ligands.42 The use of such
multifunctional nanoparticles for biomedical applications in
cancer or other diseases has great potential for diagnosis and
targeted treatment, such as targeted delivery of hydrophobic
anticancer drug combined with quantitative 19F MRI, or cell
tracking.46 In particular, 19FMRI is a quantitative technique that
is not limited by penetration depth in vivo; therefore, it would be
possible to use non-invasive in vivo imaging to quantify drug
delivery using these nanoparticles. Finally, we have shown that
this method of preparation of PLGA particles is robust, and not
signicantly aﬀected even by the addition of large amounts of
a third immiscible phase, the PFC. Overall, our results could
provide a guideline in the rational design of polymer-based
particles loaded with a third PFC phase for imaging and drug
delivery, where size, encapsulation eﬃciency and release can be
controlled.
Materials and methods
Materials
Poly(D,L-lactide-co-glycolide) (PLGA) resomer RG 502H, lacti-
de : glycolide molar ratio 50 : 50 was obtained from Evonik
Industries AG, Essen, Germany. Solvents: dichloromethane
(DCM), chloroform (Merck, Darmstadt, Germany), ethyl acetate
(AcOEt), acetone, acetonitrile (MeCN) (all from VWR, Nether-
lands), tertrahydrofuran (THF) (Sigma-Aldrich, St. Louis, MO,
USA). Perluoro-15-crown-5-ether (PFCE) was purchased from
Exuor, Round Rock USA, and Prohance from Bracco, Konstanz
Germany. Surfactants: polyvinyl alcohol (PVA, 9000–10 000 Mw,
80% hydrolized), pluronics F68, sodium cholate, poly-
vinylpyrrolidone (PVP) were purchased from Sigma-Aldrich St.
Louis, MO, USA, and Tween20 from Merck, Darmstadt, Ger-
many. Some nanoparticles were prepared with Nile blue dye
(Acros Organics, Belgium) For cell culture X-VIVO 15 medium
(Lonza, Belgium) or RPMI 1640 (Gibco, Thermo Fisher, The
Netherlands) was used. Phosphate-buﬀer saline (PBS) (Braun,
Germany) was used to resuspend nanoparticles for cell experi-
ments and for cell washing.
Particle synthesis
Particles were prepared using a miniemulsion synthesis tech-
nique. Briey, PLGA (100–200 mg), was dissolved in 3 ml of
various solvents, followed by the addition of 900 mL PFCE and
1.8 ml Prohance. For dye release and cellular uptake experi-
ments, Nile blue dye (0.2 mg) was also included in the organic
phase. The organic phase was added to 25.5 g of aqueous
solution of surfactant (0.4–2 wt%) and emulsied for 3 minutes
with the use of probe sonicator (Sonier 250, microtip 6.3 mm,
Branson Sonic Power, St. Louis, USA) at 40% amplitude. Soni-
cation was followed by overnight evaporation of solvent at room
temperature. Next, the particles were collected by centrifugation
(15 000 rpm, 20 minutes), washed several times with deionized
water, and then freeze-dried. Several parameters tested in this
protocol, including: the type of surfactant, the type of solvent,
polymer concentration (3.3, 5, 6.6 wt%) and surfactant
concentration (0.4, 1.2, 2 wt%). All particle characterization was
done on the freeze-dried samples which.
Particle characterization
Dynamic light scattering was measured at Malvern zeta sizer NS
nano (Malvern, Worcestershire, United Kingdom), using
disposable ZEN0040 cuvettes, at concentrations of 0.1 mg ml1.
Data evaluation was done with Malvern soware (Zetasizer
soware, Ink) using cumulant tting. The values are the
intensity mean of 4 independent measurements.
Multi-angle LS measurements were performed using an
ALV7004 correlator, ALV/LSE-5004 Goniometer, ALV/Dual High
QE APD detector unit with bre splitting device with a set-up of
2 oﬀ detection system and a Uniphase Model 1145P He–Ne
Laser. The laser wavelength and power were 632.8 nm and
22 mW, respectively and the temperature was controlled by
a Julabo CF41 thermostatic bath. Water for dilutions was
ltered with 0.45 mm hydrophilic lters. The data analysis was
done with HDRC soware, which was kindly provided by Prof.
Manfred Schmidt, University of Mainz, Germany. The apparent
radii of hydrodynamic radii at diﬀerent angles were calculated
using from a biexponential tting of autocorrelation function,
as it provides a good approximation to calculate the size of
monomodal samples with a non-monodisperse size distribu-
tion. The absolute inverse z-averages of hydrodynamic radii
were obtained by extrapolating q / 0. The second cumulant
values m2 were obtained from cumulant tting at q¼ 90. The m2
value is the second cumulant, obtained from the cumulant
analysis of autocorrelation function and provides a quantitative
This journal is © The Royal Society of Chemistry 2018 RSC Adv., 2018, 8, 6460–6470 | 6467
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measure for the polydispersity of the diﬀusion coeﬃcient
distribution function:
m2 ¼ (hDs2i  hDsi2)q4
where Ds is the diﬀusion coeﬃcient and q the scattering vector.
Transmission electron microscopy (TEM) was done on JEOL
TEM1010 transmission electron microscope with 35 mm lm
camera, Kodak megaplus 4CCD camera. For TEM analysis,
samples were placed on copper grids and le o/n to dry. TEM
images were then processed in ImageJ program, where 100
nanoparticles were measured to study the size distribution.
Nuclear Magnetic Resonance spectroscopy was done on
Bruker Avance III 400 MHz NMR spectrometer equipped with
a BBFO + probe. To measure the uorine content of nano-
particles, dened amount of nanoparticles was dissolved in
500 mL deuterium oxide (D2O) and mixed 100 mL 1 vol% tri-
uoroacetic acid (TFA), as an internal reference, and transferred
to NMR tubes. The interscan relaxation delay was set to
5T1,TFA* ¼ 20 s for quantication. Data analysis was carried out
with Mestrenova 10.0.2.
Cryogenic Scanning Electron Microscopy was done at JEOL
6330 Cryo Field Emission Scanning Electron Microscope
(FESEM). For cryo-SEM analysis, the samples (8 ml at concen-
tration 10 mg ml1) were pipetted in 2 rivets, which were then
placed together. Next, the samples were frozen in liquid
nitrogen slush and placed in an Oxford Alto 2500 cryo station
with a cryo-transfer device. There, the top rivet was broken and
the sample was heated to 95 C for 5 minutes, followed by
a coating of 60/40 Au/Pd and transfer to the Cryo-SEM.
Dye release
To test dye release, PLGA–PFCE nanoparticles with Nile blue,
were incubated at 37 C for several time points in pH solutions
(0.3% PVA solution with either 1 MHCl or NaOH) of 4.0, 5.5, 8.5,
followed by the DLSmeasurements (concentration 0.1 mgml1)
to detect any changes in nanoparticle size and polydispersity.
The calibration of UV/vis absorption was done with nile blue
reference at 8 diﬀerent concentrations using same solvent as for
particles. PVA was added to nile blue samples and particles, as it
was not possible to dissolve nile blue for calibration without
adding PVA. The DLS values should be treated carefully, as the
absorption of Nile blue overlaps with the DLS laser wavelength.
However, they still provide a good indication of the size trend,
as uctuations due to Brownian motion still can be detected.
Additionally, dye release from nanoparticles was tested at each
incubation time point by centrifuging the samples, collecting
the supernatant andmeasuring its absorption (JASCO V-630 UV-
vis spectrophotometer, JASCO Benelux, B.V.). Obtained data
were converted to concentrations by means of calibration
curves.
Cell culture and labeling
Peripheral bloodmononuclear cells (PBMCs) were isolated from
buﬀy coats of healthy individuals aer informed consent, using
coll density centrifugation (Lymphoprep, STEMCELL
Technologies, Vancouver, Canada). Adherent monocytes were
cultured in X-VIVO 15 medium supplemented with 2% human
serum or in RPMI-1640 medium supplemented with 10% Fetal
Bovine Serum, and in the presence of interleukin-4 (300 Uml1)
and granulocyte-monocyte colony stimulating factor
(450 U ml1) to obtain immature dendritic cells (DCs). Day 3
cells were harvested, counted and labeled with PLGA nano-
particles (resuspended in PBS shortly prior the labelling) at
concentration 2 mg of nanoparticles/1  106 cells and incu-
bated at 37 C for 1 and 24 h for confocal microscopy, 24 h for
cell migration, 72 h for viability assay and 72 h for MRI imaging.
Cell staining and confocal microscopy
The uptake of various nanoparticles containing nile blue was
conrmed with confocal microscopy. Day 3-moDCs were incu-
bated at 37 C for 1 and 24 h on glass coverslips (20 000 cells per
coverslip). At each time point the excess of the label was
removed, the coverslips with cells were washed gently with PBS,
and then the cells were xed with 2% paraformaldehyde (PFA)
for further testing with confocal microscopy. Labelled cells on
coverslips were permeabilized in CLSM buﬀer + 0.1% Saponin,
stained rst with LAMP-1 or EEA1-specic primary antibody
(Ab), followed by staining with isotype-specic AlexaFluor-
conjugated secondary Ab for intracellular compartments,
phalloidin-488 for cell membrane, and DAPI for nucleus.
Stained cells were then imaged with Olympus FV1000 Confocal
Laser Scanning Microscope. Acquired images were then pro-
cessed in the ImageJ program.
Cell migration
To study cell migration and velocity, nanoparticles were resus-
pended in PBS shortly before the labelling and added to day-3
moDCs at concentration 2 mg of nanoparticles per 1  106
cells. Cells with nanoparticles were then added to 24 well plates
and imaged for 24 hours using Okolab 2.0 microscope (Nikon
Diaphot 300 with Hamamatsu C8484-05 G CCD Camera) with
Okolab 4 well CO2 stage incubator and Okolab 2D time lapse
soware. Acquired images were then processed using ImageJ
program to measure the distance and velocity.
Cell viability
To investigate the inuence of labelling on cells viability with
performed an MTT assay. For this, 0.5  106 cells were incu-
bated in the presence of DCM, DCM + MeCN or DCM + toluene
nanoparticles for 72 hours. Each condition was done in tripli-
cate. Aer incubation, the excess of the label was removed by
gentle washing with PBS. Next, the cells were collected and
placed in at-bottom 96 well plates, washed twice in PBS (100 ml
per well) with centrifugation for 2 min between each wash. Next,
60 ml RPMImediumwith 10 ml MTT (3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide) (concentration 4 mg ml1)
was added to each well, followed by 30 minutes incubation at
37 C. Aer incubation, the plate was centrifuged for 2 min and
100 ml of lysis buﬀer (isopropanol, 10% SDS, 2 N HCL, deionized
water) was added to each well, and the plate was incubated
for 15 minutes in dark at room temperature. Before the
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measurements, samples were resuspended to remove any
precipitate of crystals. The plate was measured with iMark™
microplate reader (Bio-Rad, The Netherlands) at 595 nm.
Cells not loaded with nanoparticles were used as negative
control and cells treated with 0.2% Triton X-100 were used
a positive control.
19F Magnetic resonance imaging
19F MRI was performed on a pre-clinical 11.7 T MRI scanner
(Biospec 117/16, 500 MHz, Bruker, Ettlingen, Germany). For in
vitro imaging, 5  106 dendritic cells were co-incubated with
particles at a concentration of 10 mg ml1. Nanoparticle loaded
cells were were extensively washed to remove excess label,
before being placed in tubes, le to sediment and imaged with
the zero echo time (ZTE) sequence with the following parame-
ters: TR ¼ 2 ms, ip angle 4, matrix size ¼ 32 isotropic voxels,
FOV ¼ 60  60  60 mm, (voxel size ¼ 1.87 mm), number of
averages ¼ 128, scan time ¼ 15 minutes. Sedimented particles
(5 mg in 5 ml) in PBS were used as the reference.
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